Topic

Vitrakvi (larotrectinib)

A collection of 33 issues

How to Get Vitrakvi (Larotrectinib) Covered by Cigna in Michigan: Complete PA Guide and Appeal Scripts

Answer Box: Getting Vitrakvi Covered by Cigna in Michigan Vitrakvi (larotrectinib) requires prior authorization from Cigna for NTRK fusion-positive solid tumors that are metastatic or unresectable. Submit PA via CoverMyMeds or Evicore with molecular pathology report confirming NTRK fusion, oncologist prescription, and tumor staging documentation. If denied, Michigan residents have

Renewing Vitrakvi (Larotrectinib) Approval with Humana in Texas: Timeline, Documentation, and Bridge Options

Answer Box: Renewing Vitrakvi with Humana in Texas Humana Medicare requires prior authorization renewal for Vitrakvi (larotrectinib) every 6-12 months. Submit renewal 2-4 weeks before expiration with updated imaging showing response/stable disease, oncology notes, and liver function tests. If approval lapses, request a 31-day emergency supply under Humana'

How to Get Vitrakvi (Larotrectinib) Covered by UnitedHealthcare in North Carolina: Complete Prior Authorization and Appeals Guide

Answer Box: Quick Path to Vitrakvi Coverage To get Vitrakvi (larotrectinib) covered by UnitedHealthcare in North Carolina: Submit prior authorization via OptumRx with validated NTRK gene fusion test results, oncologist medical necessity letter documenting metastatic/unresectable disease, and prior therapy history. If denied, file internal appeal within 180 days, then

How to Get Vitrakvi (Larotrectinib) Covered by Aetna CVS Health in Washington: PA Forms, Appeals, and Cost-Saving Strategies

Answer Box: Getting Vitrakvi Covered by Aetna CVS Health in Washington Aetna CVS Health requires prior authorization for Vitrakvi (larotrectinib) with NTRK gene fusion testing documentation. Submit PA via CVS Specialty at 1-888-267-3277 with molecular pathology report showing NTRK1/2/3 fusion, oncologist prescription, and staging records. If denied, Washington

How to Get Vitrakvi (larotrectinib) Covered by UnitedHealthcare in Virginia: Prior Authorization Guide and Appeal Scripts

Answer Box: Getting Vitrakvi Covered by UnitedHealthcare in Virginia UnitedHealthcare requires prior authorization for Vitrakvi (larotrectinib) with specific criteria: confirmed NTRK gene fusion via validated testing, metastatic or unresectable solid tumor, and no known resistance mutations. Submit through OptumRx portal with molecular pathology report, staging documentation, and oncologist notes. Decisions

If Vitrakvi (Larotrectinib) Isn't Approved by Blue Cross Blue Shield of Michigan: Formulary Alternatives & Exception Paths

Answer Box: Quick Path Forward If Blue Cross Blue Shield of Michigan denies Vitrakvi (larotrectinib), you have three main options: try the covered NTRK inhibitor alternative (entrectinib/Rozlytrek if on formulary), request a formulary exception with documented medical necessity, or appeal the denial. Start by checking your specific plan'

Aetna CVS Health's Coverage Criteria for Vitrakvi (Larotrectinib) in Virginia: What Counts as "Medically Necessary"?

Answer Box: Getting Vitrakvi (Larotrectinib) Covered by Aetna CVS Health in Virginia Aetna CVS Health requires prior authorization for Vitrakvi with three key requirements: confirmed NTRK gene fusion via validated testing, metastatic/unresectable solid tumor status, and documented failure or unsuitability of standard therapies. The fastest path to approval: (1)

How to Get Vitrakvi (larotrectinib) Covered by Blue Cross Blue Shield in Pennsylvania: PA Forms, Appeals, and Success Strategies

Answer Box: Getting Vitrakvi Covered by Blue Cross Blue Shield in Pennsylvania Vitrakvi (larotrectinib) requires prior authorization from Blue Cross Blue Shield plans in Pennsylvania for NTRK fusion-positive solid tumors. The fastest path to approval: (1) Submit PA with confirmed NTRK fusion testing results and documentation of metastatic/unresectable disease,

How to Get Vitrakvi (Larotrectinib) Covered by Aetna CVS Health in Illinois: PA Forms, Appeal Scripts & Timeline Guide

Quick Answer: Aetna CVS Health requires prior authorization for Vitrakvi (larotrectinib) with documented NTRK gene fusion testing and evidence of metastatic/unresectable disease. Submit PA via CVS Specialty at 1-888-267-3277 with molecular pathology report, oncologist notes, and prior therapy documentation. If denied, appeal within 180 days using medical necessity letter

How to Get Vitrakvi (larotrectinib) Covered by Blue Cross Blue Shield of Illinois: PA Forms, Appeal Scripts & NTRK Testing Requirements

Answer Box: Getting Vitrakvi Covered by BCBS Illinois Blue Cross Blue Shield of Illinois (BCBSIL) requires prior authorization for Vitrakvi (larotrectinib), which is not on their 2025 formulary. Your fastest path to approval: (1) Submit a complete PA request with validated NTRK fusion testing results, (2) Include medical necessity documentation